PHILADELPHIA, May 6 /PRNewswire/ --
- Manuscript Central v4.2 to Offer its Customers Access to Services Verifying the Originality of All Scholarly Content Submitted on the System
The Scientific business of Thomson Reuters today announced that Manuscript Central's online workflow system will incorporate the iThenticate checking tool into its submission and peer review process, and will develop suitable policies and guidelines. CrossRef recently announced an agreement with iParadigms, LLC to launch the CrossCheck service to aid in verifying the originality of scholarly content. Following on the success of CrossRef's recent pilot of CrossCheck, the service is scheduled to go live in June and will be offered via Manuscript Central.
Manuscript Central's integration with the iThenticate tool will allow CrossCheck member journals and publishers to send submissions for comparison to the iThenticate service at any point in the peer review or acceptance workflow. With status indicators and a quick view of comparison results, journals will be enabled to investigate suspected documents much further back in the peer review process, potentially saving valuable time and resources in the peer review workflow.
"We are very excited to be a part of the initial roll-out of the plagiarism detection initiative as it underscores the importance we place on helping our customers control the quality of their manuscript submission and online peer review," said Keith MacGregor, Executive Vice President of Thomson Reuters Academic and Government Market. "We are confident this endeavor will ultimately better the quality and accuracy of published research works."
Manuscript Central is an innovative, web-based, database-driven peer review and online submission program for scholarly publishers. Manuscript Central automates manuscript submission to journals and allows for easy administrative, editing and reviewing capabilities, so its customers can focus on content, not on process. With more than 200 societies and publishers, 2,400 books and journals, 70,000 monthly submissions and 5 million registered users, Manuscript Central is the proven industry leader.
The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Our authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success.
CrossRef (http://www.crossref.org) is a non-profit membership association founded and directed by publishers. Its mission is to enable easy identification and use of trustworthy electronic content by promoting the cooperative development and application of a sustainable infrastructure.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI); Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and Nasdaq (Nasdaq: TRIN). For more information, go to www.thomsonreuters.com.
Nikki Haffey, Scientific, +1-434-817-2040, email@example.com